25 Jun 2020 15:16
25 June 2020
Microsaic Systems plc
("Microsaic" or the "Company")
Result of AGM
Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting today were duly passed on a poll, the results of which are set out below:
Â
 | Ordinary resolutions | Votes for | % of votes cast | Votes against | % votes cast | Votes withheld |
1 | To approve the audited accounts of the Company for the year ended on 31 December 2019, together with the Directors' Report and Auditors' Report thereon | 329,369,671 | 100.00 | - | - | 500 |
2 | To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the remuneration of the auditors | 329,176,504 | 99.94 | 193,667 | 0.06 | - |
3 | To re-appoint Bevan Metcalf as a Director of the Company | 329,370,171 | 100.00 | - | - | - |
4 | To authorise the Directors to allot equity securities up to an aggregate nominal amount of £380,304 | 329,176,504 | 99.94 | 193,667 | 0.06 | - |
 | Special resolution | Votes for | % of votes cast | Votes against | % votes cast | Votes withheld |
5 | To dis-apply statutory pre-emption rights | 328,461,504 | 99.73 | 908,667 | 0.27 | - |
Â
Â
Enquiries:
Â
Microsaic Systems plc | +44 (0) 1483 751 577 |
Glenn Tracey, CEO | Â |
Bevan Metcalf, FD Â | Â |
N+1 Singer (Nominated Adviser & Joint Broker) | +44 (0)20 7496 3000 |
Aubrey Powell / George Tzimas (Corporate Finance) | Â |
Tom Salvesen (Corporate Broking) Â | Â |
WH Ireland Limited (Joint Broker) | +44 (0)20 7220 1666 |
James Joyce (Corporate Finance) | Â |
Jasper Berry (Corporate Broking) | Â |
Â
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.
Â
Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com.
Â
Â